2017
A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia
Gunduz‐Bruce H, Kenney J, Changlani S, Peixoto A, Gueorguieva R, Leone C, Stachenfeld N. A translational approach for NMDA receptor profiling as a vulnerability biomarker for depression and schizophrenia. Quarterly Journal Of Experimental Physiology And Cognate Medical Sciences 2017, 102: 587-597. PMID: 28294453, DOI: 10.1113/ep086212.Peer-Reviewed Original ResearchConceptsSubgroup of patientsHealthy control subjectsNMDA receptorsControl subjectsDepressed patientsAVP releaseAnimal studiesSchizophrenic subjectsTranslational approachVivo evidenceRecent clinical trialsNMDA receptor functionPlasma arginine vasopressin concentrationNMDA receptor activityHypertonic saline infusionNMDA antagonist ketamineArginine vasopressin concentrationHypertonic salineInverse associationClinical trialsHealthy controlsSaline infusionGlutamate signalingSchizophrenic patientsVasopressin concentration
2005
Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence
Perry E, Gil R, Miles D, Brenner L, Macdougall L, Johnson R, Degen K, Gueorguieva R, Petrakis I, Krystal J, D'Souza D. Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence. Journal Of Dual Diagnosis 2005, 1: 37-47. DOI: 10.1300/j374v01n01_04.Peer-Reviewed Original ResearchCocaine abusePsychiatric symptomsCocaine cravingCatecholamine reuptake inhibitorCurrent antipsychotic medicationsCocaine consumptionPlacebo groupAntipsychotic pharmacotherapyReuptake inhibitorsAntipsychotic medicationAntipsychotic treatmentComorbid schizophreniaSchizoaffective patientsSubstance abuse issuesSchizophrenic patientsPatientsSchizoaffective disorderSchizophrenia patientsNatural historyMazindolPilot studyGroup therapySchizophreniaSymptomsAbuse issues